Correlation of serum vascular adhesion protein-1 with airflow limitation and quality of life in stable chronic obstructive pulmonary disease.

Abstract

The serum vascular adhesion protein-1 (VAP-1) level increases in chronic inflammatory diseases. The present study aimed to examine serum VAP-1 level in patients with stable chronic obstructive pulmonary disease (COPD) and the correlation of this marker with airflow limitation and health-related quality of life using the COPD Assessment Test (CAT). We measured serum VAP-1 level in 43 patients with stable COPD and 30 control subjects and compared them with airflow limitation according to the COPD stage in the Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) criteria, peripheral O2 saturation (SpO2), and CAT score. We also tested the association of serum VAP-1 level with COPD patients' clinical parameters. Serum VAP-1 level increased with increasing severity of COPD according to the GOLD classification (P=0.007). It also increased in patients with high CAT groups and high values on the modified Medical Research Council dyspnea scale (P=0.012 and P=0.015, respectively). In addition, there was a significant positive correlation between serum VAP-1 level and both SpO2 and CAT score (r=-0.404, P=0.007; r=0.482, P=0.001, respectively). The study showed that serum VAP-1 level increased with an increasing severity of obstruction in patients with stable COPD. This increase was associated with a reduced quality of life and increased severity of hypoxia. These results suggest that inhibiting serum VAP-1 level in COPD patients may be useful in managing the disease.